Savara(US:SVRA) Globenewswire·2025-11-02 23:47Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 7, 2025 [2] - The lawsuit claims that Savara's defendants made false or misleading statements regarding the approval process of the MOLBREEVI Biologics License Application (BLA) [4] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3] - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking No. 1 for settlements in 2017 [3] Group 3: Case Specifics - The lawsuit alleges that the defendants failed to disclose critical information about the MOLBREEVI BLA, which affected the likelihood of FDA approval and the company's capital needs [4] - The claims suggest that the public statements made by the defendants were materially false and misleading, leading to investor damages when the true information became public [4]